Cutaneous Leishmaniasis in Ethiopia causes severe dermatological mutilations. Forms that require systemic treatment are cLCL, MCL, and DCL. National guidelines recommend equally all drugs that are also used for VL treatment. Miltefosine is one of these recommended medications but remains underused due to scarcity of drugs. Outcomes of patients receiving miltefosine have never been documented systematically in Ethiopia until today. This is needed to provide evidence to advocate for increased access to miltefosine in Ethiopia, and to establish baseline data for future research on CL treatment options. The aim of this study is to document treatment outcomes of patients with cLCL, MCL, and DCL receiving systemic treatment using miltefosine within a routine care setting located in an endemic area in Ethiopia.
Study Type
OBSERVATIONAL
Enrollment
94
Patients who receive miltefosine in the routine setting will be asked to participate in the study to document their outcomes
Boru Meda Hospital
Boru, Ethiopia
Gondar University Hospital
Gonder, Ethiopia
Assess final treatment response
proportion of index lesions with cure, good, partial and no treatment response
Time frame: Day 90
Early and late treatment response
Proportion of index lesions with cure, good, partial and no treatment response at Day 28 and Day 180
Time frame: Day 28, Day 180
Treatment failure
Proportion of index lesions with relapse or failure at Day 90 and Day 180
Time frame: Day 90, Day 180
Adherence
Proportion of patients with excellent (0 missed), good (1-3 missed), mediocre (4-8 missed), and poor (\<=9 missed) adherence
Time frame: Day 28
Predictors of cure
Covariate-adjusted risk ratios of factors associated with cure of index lesions at Day 90
Time frame: Day 90
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.